1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Drugs In Development, 2022, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 27, 102, 78, 2 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 8 and 1 molecules, respectively.
Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Fallopian Tube Cancer - Overview
- Fallopian Tube Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Fallopian Tube Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Fallopian Tube Cancer - Companies Involved in Therapeutics Development
- Fallopian Tube Cancer - Drug Profiles
- Fallopian Tube Cancer - Dormant Projects
- Fallopian Tube Cancer - Discontinued Products
- Fallopian Tube Cancer - Product Development Milestones
- Featured News & Press Releases
- Jul 22, 2022: EMA recommends restricting use of cancer medicine Rubraca
- Jul 05, 2022: EMA recommends granting a marketing authorisation for biosimilar Bevacizumab
- May 31, 2022: Greenfire Bio to update progress on phase 1 clinical trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022
- May 19, 2022: EMA starts review of rucaparib
- Feb 24, 2022: Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
- Dec 10, 2021: Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea
- Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) first listing for Pamiparib
- Feb 25, 2021: Viatris receives positive CHMP opinion for Abevmy for use as treatment of various cancers
- Dec 28, 2020: Zai Lab announces inclusion of ZEJULA (Niraparib) in China’s National Reimbursement Drug List
- Oct 05, 2020: Elevar Therapeutics and Taiba Middle East FZ partner to commercialize Apealea (paclitaxel micellar) in the Middle East and North Africa region
- Jul 27, 2020: Elevar Therapeutics and Tanner Pharma Group announce global named patient program to provide access to Apealea (paclitaxel micellar)
- Jun 22, 2020: Preclinical data for PRGN-3005 UltraCAR-T demonstrate superior expansion and persistence of UltraCAR-T compared to traditional CAR-T
- Apr 30, 2020: GSK gets FDA approval for expanded use of ovarian cancer drug Zejula
- Apr 20, 2020: Sutro Biopharma to host conference call, to provide clinical update on its STRO-002 Antibody-Drug Conjugate
- Mar 16, 2020: Zai Lab announces acceptance of sNDA submission of ZEJULA (Niraparib) for first-line maintenance treatment of ovarian cancer in China by the NMPA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Fallopian Tube Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Fallopian Tube Cancer - Dormant Projects, 2022
- Fallopian Tube Cancer - Discontinued Products, 2022
- Fallopian Tube Cancer - Discontinued Products, 2022 (Contd..1)
- Number of Products under Development for Fallopian Tube Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- AbbVie Inc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- AiVita Biomedical Inc
- Akeso Inc
- Aldeyra Therapeutics Inc
- Alkermes Plc
- Alpine Immune Sciences Inc
- Amgen Inc
- Aminex Therapeutics Inc
- Anixa Biosciences Inc
- Apexigen Inc
- APIM Therapeutics AS
- Apollomics Inc
- Aprea Therapeutics Inc
- Aravive Inc
- Arch Oncology Inc
- Artios Pharma Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Basilea Pharmaceutica Ltd
- Bayer AG
- BeiGene Ltd
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- BioIntegrator
- BioInvent International AB
- BioNTech SE
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Celldex Therapeutics Inc
- Celltrion Inc
- Celsion Corp
- Clovis Oncology Inc
- Coherent Biopharma
- Compugen Ltd
- Corcept Therapeutics Inc
- Cotinga Pharmaceuticals Inc
- Cristal Therapeutics BV
- CSPC Pharmaceutical Group Ltd
- Daiichi Sankyo Co Ltd
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- ENB Therapeutics LLC
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Genelux Corp
- Genentech USA Inc
- Genmab AS
- Gilead Sciences Inc
- Gradalis Inc
- Greenfire Bio LLC
- GSK plc
- Harpoon Therapeutics Inc
- Hutchison MediPharma Ltd
- I-Mab
- Idience Co Ltd
- ImmunityBio Inc
- Immunocore Limited
- ImmunoGen Inc
- Immunotech Biopharm Ltd
- IMPACT Therapeutics Inc
- IMV Inc
- Incyte Corp
- Innovent Biologics Inc
- Instil Bio Inc
- InxMed (Beijing) Co Ltd
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Jina Pharmaceuticals Inc
- Johnson & Johnson
- Karyopharm Therapeutics Inc
- Kidswell Bio Corp
- Laekna Therapeutics Shanghai Co Ltd
- Leap Therapeutics Inc
- Lee's Pharmaceutical Holdings Ltd
- Lokon Pharma AB
- MabVax Therapeutics Holdings Inc
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Mersana Therapeutics Inc
- Mina Therapeutics Ltd
- Mycenax Biotech Inc
- Northlake International LLC
- Novartis AG
- NuCana Plc
- Nurix Therapeutics Inc
- Nuvation Bio Inc
- OBI Pharma Inc
- OncoC4 Inc
- Oncoinvent AS
- Onconic Therapeutics Co Ltd
- OncoQuest Inc
- Oncovir Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Onxeo SA
- Pfizer Inc
- Pharma Mar SA
- PharmAbcine Inc
- Pharmicell Co Ltd
- Pharos iBio Co Ltd
- Pionyr Immunotherapeutics Inc
- Plexxikon Inc
- Precigen Inc
- Prestige BioPharma Ltd
- ProLynx LLC
- PsiOxus Therapeutics Ltd
- PTC Therapeutics Inc
- R-Pharm US LLC
- Recordati SpA
- Regeneron Pharmaceuticals Inc
- RemeGen Co Ltd
- Rhizen Pharmaceuticals SA
- Rigel Pharmaceuticals Inc
- Samyang Biopharmaceuticals Corp
- Sanofi
- Scancell Holdings Plc
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Senhwa Biosciences Inc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shattuck Labs Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Sorrento Therapeutics Inc
- STADA Pharmaceuticals (Asia) Ltd
- Sumitomo Pharma Co Ltd
- Sutro Biopharma Inc
- Synermore Biologics Co Ltd
- SynOx Therapeutics Ltd
- TILT Biotherapeutics Ltd
- Tmunity Therapeutics Inc
- Toray Industries Inc
- Transgene SA
- Ultimovacs AS
- Vascular Biogenics Ltd
- Verastem Inc
- Viatris Inc
- Vigeo Therapeutics Inc
- Vivesto AB
- Vyriad Inc
- Xencor Inc
- Xynomic Pharmaceuticals Holdings Inc
- Zenith Epigenetics Ltd
- Zentalis Pharmaceuticals Inc
- Zymeworks Inc
